Browsing by Author "Chizzolini C."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database
    (2010) Avouac J.; Walker U.; Tyndall A.; Kahan A.; Matucci-Cerinic M.; Allanore Y.; Miniati I.; Müller A.; Iannone F.; Giacomelli R.; Distler O.; Becvar R.; Sierakowsky S.; Kowal-Bielecka O.; Coelho P.; Cabane J.; Cutolo M.; Shoenfeld Y.; Valentini G.; Rovensky J.; Riemekasten G.; Nicoara I.; Vlachoyiannopoulos P.; Caporali R.; Jiri S.; Inanc M.; Gorska I.Z.; Carreira P.; Novak S.; Czirjak L.; Ramos F.O.; Jendro M.; Chizzolini C.; Kucharz E.J.; Richter J.; Cozzi F.; Rozman B.; Mallia C.M.; Gabrielli A.; Farge D.; Kiener H.P.; Schöffel D.; Sticherling M.; Airo P.; Wollheim F.; Martinovic D.; Trotta F.; Hunzelmann N.; Jablonska S.; Reich K.; Bombardieri S.; Siakka P.; Pellerito R.; Bambara L.M.; Morovic-Vergles J.; Denton C.; Hinrichs R.; Van Den Hoogen F.; Damjanov N.; Kötter I.; Ortiz V.; Heitmann S.; Krasowska D.; Seidel M.; Hasler P.; Van Laar J.M.; Kaltwasser J.P.; Foeldvari I.; Juan Mas A.; Bajocchi G.; Wislowska M.; Pereira Da Silva J.A.; Jacobsen S.; Worm M.; Graniger W.; Kuhn A.; Stankovic A.; Cossutta R.; Majdan M.; Rajcevska L.D.; Tikly M.; Nasonov E.L.; Steinbrink K.; Herrick A.; Müller-Ladner U.; Dinc A.; Scorza R.; Sondergaard K.; Indiveri F.; Nielsen H.; Szekanecz Z.; Silver R.M.; Antivalle M.; Espinosa I.B.; García De La Pena Lefebvre P.; Midtvedt O.; Launay D.; Valesini F.; Tuvik P.; Ionescu R.M.; Del Papa N.; Pinto S.; Wigley F.; Mihai C.; Capranu M.S.; Sunderkötter C.; Jun J.B.; Derk C.; Alhasani S.; Distler J.H.; Ton E.; Soukup T.; Seibold J.; Zeni S.; Nash P.; Mouthon L.; De Keyser F.; Duruöz M.T.; Cantatore F.P.; Strauss G.; Von Mülhen C.A.; Pozzi M.R.; Eyerich K.; Szechinski J.; Keiserman M.; Houssiau F.A.; Rom-Ivorra J.A.; Krummel-Lorenz B.; Aringer M.; Westhovens R.; Bellisai F.; Mayer M.; Stoeckl F.; Üprus M.; Volpe A.; Buslau M.; Yavuz S.; Granel B.; Feijó A.V.; Del Galdo F.; Popa S.; Zenone T.; Machado X.R.; Pileckyte M.; Stebbings S.; Mathieu A.; Tulli A.; Tourinho T.; Souza R.; Acayaba De Toledo R.; Stamp L.; Solanki K.; Veale D.; Neto J.F.M.; Bagnato G.F.; Loyo E.; Toloza S.; Li M.; Mohamed W.A.A.A.; Cobankara V.; Olas J.; Salsano F.; Oksel F.; Tanaseanu C.M.; Foti R.; Ancuta C.; Vonk M.; Caramashi P.; Beretta L.; Balbir A.; Shine B.; Chiàla A.; Simic K.P.; Ghio M.; Stamenkovic B.; Rednic S.; Host N.; Hachulla E.; Furst D.E.
    Objective. To determine the prevalence of and independent factors associated with joint involvement in a large population of patients with systemic sclerosis (SSc). Methods. This study was cross-sectional, based on data collected on patients included in the European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) registry. We queried this database to extract data regarding global evaluation of patients with SSc and the presence of any clinical articular involvement: synovitis (tender and swollen joints), tendon friction rubs (rubbing sensation detected as the tendon was moved), and joint contracture (stiffness of the joints that decreased their range of motion). Overall joint involvement was defined by the occurrence of synovitis and/or joint contracture and/or tendon friction rubs. Results. We recruited 7286 patients with SSc; their mean age was 56 ± 14 years, disease duration 10 ± 9 years, and 4210 (58%) had a limited cutaneous disease subset. Frequencies of synovitis, tendon friction rubs, and joint contractures were 16%, 11%, and 31%, respectively. Synovitis, tendon friction rubs, and joint contracture were more prevalent in patients with the diffuse cutaneous subset and were associated together and with severe vascular, muscular, renal, and interstitial lung involvement. Moreover, synovitis had the highest strength of association with elevated acute-phase reactants taken as the dependent variable. Conclusion. Our results highlight the striking level of articular involvement in SSc, as evaluated by systematic examination in a large cohort of patients with SSc. Our data also show that synovitis, joint contracture, and tendon friction rubs are associated with amore severe disease and with systemic inflammation. The Journal of Rheumatology Copyright © 2010. All rights reserved.
  • No Thumbnail Available
    Item
    Is there a role for TNF-α antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique
    (2011) Distler J.H.W.; Jordan S.; Airò P.; Alegre-Sancho J.J.; Allanore Y.; Balbir Gurman A.; Caporali R.; Caramaschi P.; Carreira P.E.; Chizzolini C.; Cutolo M.; Tuncay Duruöz M.; Farge-Bancel D.; Hesselstrand R.; Iannone F.; De Keyser F.; Kucharz E.J.; Launay D.; García De La Peña Lefebvre P.; Lukacova O.; Marasini B.; Martinovic D.; Marques Neto J.F.; Radic M.; Rednic S.; Riemekasten G.; Rovensky J.; Seidel M.F.; Senel S.; Smith V.; Sunderkötter C.; Ton E.; Van Laar J.M.; Matucci-Cerinic M.; Müller-Ladner U.; Distler O.
    Objective: To obtain experiences and expert opinion on treatment of SSc patients with TNF-α antagonists. Methods: An investigation was carried out among the EUSTAR centres into their expertise on use of TNF-α antagonists. Assessment forms on the frequency of TNF-α inhibitor use were distributed to EULAR Scleroderma Trials and Research Group (EUSTAR) centres. Afterwards, a three round Delphi exercise was performed to obtain expert consensus on the use of TNF-α inhibitors in SSc. Results: Seventy-nine centres returned information on use of TNF-α antagonists in SSc patients. A total of 65 patients were treated with TNF-a inhibitors in 14 different centres. Forty-eight of the 65 patients treated with TNF-α inhibitors improved. Improvement was mainly seen in patients with arthritis, whereas the effects on fibrosis varied. In the first round of the subsequent Delphi approach, 71 out of 79 experts stated that they would use TNF-α antagonists in SSc. Arthritis was suggested as an indication for TNFa antagonists by 75% of the experts. However, after the third stage of the Delphi exercise, the acceptance for the off-label use of TNF-a antagonists decreased and 59% recommended that TNF-α antagonists should not be used or only used in clinical trials in SSc patients, while 38% of the experts suggested the use of TNF-a antagonists for arthritis associated with SSc. Conclusions: Most of the experts do not recommend the routine use of TNF-a antagonists in systemic sclerosis. Arthritis might be a potential indication in SSc, although controlled clinical trials with TNF-α antagonists are needed before general recommendations can be given. © Copyright Clinical and Experimental Rheumatology 2011.